Your AI-Trained Oncology Knowledge Connection!
The FDA has added 3 months to the review period for a new drug application for quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia, allowing the agency to review additional data provided by Daiichi Sankyo.
J. Stuart Salmon, MD, highlights first-, second-, and third-line treatment options for patients with gastric and gastroesophageal cancer following recent clinical trial findings and regulatory approvals.
Terrence J. Bradley, MD, discusses approved and investigational agents that patients with myelofibrosis and polycythemia vera can turn to.
Kunal C. Kadakia, MD, highlight key takeaways from the the PROMID, CLARINET, and NETTER-1 trials and explains how their findings have been applied to clinical practice.
The European Commission has approved dacomitinib for the frontline treatment of adult patients with locally advanced or metastatic non–small cell lung cancer with EGFR-activating mutations.
Joseph D. Rosenblatt, MD, discusses how advances made in chronic lymphocytic leukemia are changing the outlook for patients and predicts what can be accomplished in the near future.
While complex, criteria for diagnosing transplant-associated thrombotic microangiopathy following hematopoietic stem cell transplantation should be closely followed and should begin with screening.
Mario M. Leitao, Jr, MD, FACOG, FACS, Leitao highlights the decision-making process for the placement of surgery in patients with newly diagnosed advanced ovarian cancer, as well as the use of hyperthermic intraperitoneal chemotherapy.
Cyclophosphamide administered alone or in combination with other agents is an effective prophylactic treatment for graft-versus-host disease, regardless of stem cell source, conditioning intensity, or patient age in 10/10 and 9/10 human leukocyte antigen matched unrelated donor hematopoietic stem cell transplantation recipients.
Jimmy J. Hwang, MD, sheds light on updates in both metastatic pancreatic cancer and advanced hepatocellular carcinoma that have created new complexities for researchers.
The development of high-grade acute graft-versus-host disease following hematopoietic stem cell transplantation poses the highest risk for transplant-associated thrombotic microangiopathy in pediatric patients.
Celestia Higano, MD, FACP, discusses the potential for PARP inhibitors in patients with metastatic castration-resistant prostate cancer, as well as the role of darolutamide in nonmetastatic disease.
Patients with multiple myeloma who relapsed following allogeneic stem cell transplantation and also failed several posttransplant therapies demonstrated a strong response to daratumumab salvage therapy.
A novel treatment of ruxolitinib combined with etanercept led to encouraging response and survival rates in patients who developed grades 3/4 steroid-resistant acute graph-versus-host disease after undergoing allogeneic stem cell transplantation.
An accelerated filing of a biologics license application is planned for [fam-] trastuzumab deruxtecan (DS-8201) as a treatment for patients with HER2-positive metastatic breast cancer previously treated with ado-trastuzumab emtansine.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted positive opinions to 2 triplet regimens with immunomodulatory agents for patients with multiple myeloma.
The frontline combination of fulvestrant and anastrozole resulted in a sustained benefit in progression-free survival and a significant improvement in overall survival compared with anastrozole alone in patients with postmenopausal, HR–positive metastatic breast cancer, according to long-term results of the SWOG S0226 trial.
Although it has been difficult to identify a specific target for triple-negative breast cancer, several therapeutic classes are showing great promise.
The use of prophylactic cranial irradiation failed to demonstrate a statistically significant improvement in overall survival over observation in patients with locally advanced stage III non–small cell lung cancer; however, the modality did improve disease-free survival and decreased the risk of brain metastasis.
Enfortumab vedotin showed strong clinical activity in patients with locally advanced or metastatic urothelial carcinoma who previously received both platinum-containing chemotherapy and immune checkpoint therapy, according to topline results from the pivotal phase II EV-201 trial.
The FDA has proposed amendments to key policies to modernize breast cancer screening and improve mammography services, in order to enable healthcare providers and patients to make more informed medical decisions
Sequential administration of CAR T-cell therapy targeting both the CD19 and CD22 antigens demonstrated high complete remission rates and improved long-term survival in patients with relapsed/refractory B-cell acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplant.
A Type II variation application has been submitted to the European Medicines Agency for the 4-drug regimen of daratumumab, bortezomib, thalidomide, and dexamethasone as a treatment for patients with newly diagnosed multiple myeloma who are eligible to undergo autologous stem cell transplant.
Treosulfan added to fludarabine demonstrated an improvement in event-free and overall survival compared with busulfan/fludarabine as a treatment for patients with acute myeloid leukaemia or myelodysplastic syndrome who are scheduled for allogeneic hematopoietic stem cell transplantation but are considered ineligible for standard myeloablative conditioning.
Mohamed E. Salem, MD, highlights ongoing research efforts to potentially improve survival in patients with metastatic colorectal cancer.
The FDA has granted a breakthrough therapy designation to the combination of ivosidenib and azacitidine for the treatment of newly diagnosed patients with IDH1-mutant acute myeloid leukemia ≥75 years old or are ineligible for intensive induction chemotherapy.
Ali McBride, PharmD, MS, BCOP, was named 2019-2020 President of the Association of Community Cancer Centers during its 45th Annual Meeting and Cancer Center Business Summit on March 22, 2019, in Washington, D.C.
Benjamin P. Levy, MD, discusses the rise of checkpoint inhibitors in small cell lung cancer, an emerging targeted agent in non–small cell lung cancer, and the road that lies ahead in the overall landscape.
A supplemental biologics license application has been submitted to the FDA for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
James E. Hoffman, MD, discusses the current treatment options available for patients with multiple myeloma, underscores remaining challenges in the space, and shares predictions for where the field is headed.